Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) have been given a consensus recommendation of “Hold” by the six ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $19.33.
Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Thursday, February 8th. StockNews.com cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, April 6th.
View Our Latest Report on Enanta Pharmaceuticals
Institutional Investors Weigh In On Enanta Pharmaceuticals
Enanta Pharmaceuticals Stock Down 0.9 %
Shares of NASDAQ ENTA opened at $12.37 on Friday. The firm’s 50-day moving average price is $14.82 and its 200-day moving average price is $11.84. The company has a market cap of $261.75 million, a PE ratio of -1.89 and a beta of 0.47. Enanta Pharmaceuticals has a 52-week low of $8.08 and a 52-week high of $37.75.
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last announced its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. The company had revenue of $18.00 million for the quarter, compared to analysts’ expectations of $22.74 million. As a group, equities research analysts anticipate that Enanta Pharmaceuticals will post -4.9 EPS for the current fiscal year.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.
Featured Articles
- Five stocks we like better than Enanta Pharmaceuticals
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- Want to Profit on the Downtrend? Downtrends, Explained.
- How to Use Put Debit Spreads to Profit From Falling Stocks
- High Flyers: 3 Natural Gas Stocks for March 2022
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.